Abstract
Study design: A randomized, prospective, double-blind, placebo-controlled clinical trial.
Objectives: To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI).
Setting: County and University Teaching Hospital, Miami, FL, USA.
Methods: A total of 76 patients were enrolled in the study. Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. Prevention was started 3 weeks after spinal cord injury (SCI). In both groups of patients there was similar age as well as the level of SCI and ASIA impairment scale. Two methods were used to diagnose early HO, clinical symptoms and bone scintigraphy. Radiography was used for diagnosis of late stages of HO development.
Results: A significantly lower incidence of HO was found in the rofecoxib group (13.4%) than in the placebo group (33.3%: P<0.05). In patients receiving rofecoxib, there was a 2.5 times lower relative risk of developing HO than in the placebo group (95% CI, 2.3–6). There were no patients who discontinued the study due to adverse effects of medication.
Conclusion: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abrasion AS . Bone disturbances in injuries to spinal cord and cauda equina (paraplegia): their prevention by ambulation. J Bone Joint Surg 1947; 30: 982–991.
Heilbuoss N, Kuhn Jr WG . Erosive bone lesions and soft tissue ossification associated with spinal cord injuries (paraplegia). Radiology 1947; 48: 579–585.
Liberson M . Soft tissue calcifications in cord lesions. JAMA 1953; 152: 1010–1015.
Banovac K, Gonzalez F . Evaluation and management of heterotopic ossification in patients with spinal cord injury. Spinal Cord 1997; 35: 158–162.
Garland DE . A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop Rel Res 1991; 263: 13–29.
Garland DE, Orwin JF . Resection of heterotopic ossification in patients with spinal cord injuries. Arch Phys Med Rehab 1987; 242: 169–176.
Puras JE, Miller MD, Rosier RN . Pathologic bone formation. Clin Orthop Rel Res 1989; 245: 269–281.
Ekelund A, Brosjo O, Nilsson OS . Experimental induction of heterotopic bone. Clin Orthop Rel Res 1990; 263: 102–112.
Kjaersgaard AP, Schmidt SA . Total hip arthroplasty. The role of anti-inflammatory medication in prevention of heterotopic ossification. Clin Orthop Rel Res 1991; 263: 78–86.
McMahon JS, Waddell JP, Matron J . Effect of short course indomethacin on heterotopic bone formation after uncemented total hip arthroplasty. J Arthroplasty 1991; 6: 259–264.
Banovac K, Williams JM, Patrick LD, Haniff YM . Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord 2001; 39: 370–374.
Vane JR, Botting RM . Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998; 47(Suppl 2): 578–587.
Banovac K, Gonzalez F, Wade N, Bowker JJ . Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Paraplegia 1993; 31: 660–666.
Banovac K, Gonzalez F, Renfree KJ . Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med 1997; 20: 60–65.
Ritter MA, Gioe TJ . The effect of indomethacin on para-articular ectopic ossification following total hip arthroplasty. Clin Orthop 1982; 167: 113–117.
Schmidt S et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double blind clinical trial. J Bone Joint Surg 1988; 70A: 834–838.
Langman MY et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929–1933.
Bombardier C et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2002; 343: 1520–1528.
Laine L et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2- specific inhibitor, with that of ibuprofen on the gastrointestinal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776–783.
Stover SL, Nieman KMW, Tullos J . Experience with surgical resection of heterotopic bone in spinal cord injury patients. Clin Orthop Rel Res 1991; 263: 71–77.
Schurch B, Capaul M, Vallaton MB, Rossier AB . Prostaglandin E2 measurements: their value in the early diagnosis of heterotopic ossification in spinal cord injury patients. Arch Phys Med Rehabil 1997; 78: 687–691.
Biering-Sorenson F, Tonderola F . Indomethacin and etidronate for the prevention of recurrence of heterotopic ossification after surgical resection. Paraplegia 1993; 31: 513–515.
Bruder SP, Fink DJ, Caplan AI . Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994; 13: 721–727.
Wozney JM . The bone morphogenic protein family and osteogenesis. Mol Reprod Dev 1992; 32: 160–167.
Bosch P et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res 2000; 18: 933–944.
Zhang X et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblasts lineage and is critically involved in bone repair. J Clin Invest 2002; 109: 1405–1415.
Yamaguchi A et al. Recombinant human bone morphogenic protein–2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 1991; 113: 681–687.
Chen D et al. Differentiational roles for bone morphogenic protein receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblasts and adipocytes lineages. J Cell Biol 1998; 142: 295–305.
Urist MR . Bone morphogenic protein: the molecularization of skeletal system development. J Bone Miner Res 1997; 12: 343–346.
Wozney JM et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528–1534.
Cannon GW et al. Rofecoxib, and a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheumatism 2000; 43: 978–987.
Geba GP et al. Efficacy of rofecoxib, celebrex and acetaminophen in osteoarthritis of the knee. JAMA 2002; 287: 64–71.
Day R et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781–1787.
Watson DJ et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160: 2998–3003.
Acknowledgements
This work was supported by Miami Project to Cure Paralysis and a generous donation from Mr and Mrs John Vondra.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Banovac, K., Williams, J., Patrick, L. et al. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 42, 707–710 (2004). https://doi.org/10.1038/sj.sc.3101628
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.sc.3101628
Keywords
This article is cited by
-
Neurological heterotopic ossification: novel mechanisms, prognostic biomarkers and prophylactic therapies
Bone Research (2020)
-
Heterotopic Ossification After Spinal Cord Injury: Current Clinical Approaches
Current Physical Medicine and Rehabilitation Reports (2020)
-
When the Nervous System Turns Skeletal Muscles into Bones: How to Solve the Conundrum of Neurogenic Heterotopic Ossification
Current Osteoporosis Reports (2020)
-
Use of nonsteroidal anti-inflammatory drugs to prevent heterotopic ossification after spinal cord injury: a retrospective chart review
Spinal Cord (2019)
-
Development of heterotopic ossifications, blood markers and outcome after radiation therapy in spinal cord injured patients
Spinal Cord (2015)
